Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | MMP14 | P50281 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6242797 | 1.00 | ADAMTS4 (0.56) | ADAMTS4TAAR1PTGS2MMP8MMP14 | |
| SCHEMBL1312515 | 1.00 | ADAMTS4 (0.56) | ADAMTS4TAAR1PTGS2MMP8MMP14 | |
| Hydrochloric Acid SCHEMBL7315658 | 0.98 | ADAMTS4 (0.54) | ADAMTS4TAAR1PTGS2MMP8MMP14 | |
| SCHEMBL33928 | 0.88 | TDP1 (0.56) | ADAMTS4GAAALDH1A1LMNACYP3A4 | |
| SCHEMBL1331551 | 0.88 | TDP1 (0.56) | ADAMTS4GAAALDH1A1LMNACYP3A4 | |
| SCHEMBL33927 | 0.88 | TDP1 (0.56) | ADAMTS4GAAALDH1A1LMNACYP3A4 | |
| SCHEMBL1330911 | 0.88 | TDP1 (0.56) | ADAMTS4GAAALDH1A1LMNACYP3A4 | |
| SCHEMBL1531678 | 0.88 | TDP1 (0.56) | ADAMTS4GAAALDH1A1LMNACYP3A4 | |
| Hydrochloric Acid SCHEMBL10424136 | 0.86 | TDP1 (0.54) | ADAMTS4GAAALDH1A1LMNACYP3A4 | |
| Methane SCHEMBL6442579 | 0.86 | TDP1 (0.54) | ADAMTS4GAAALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 713 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083944-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-03-14 | — | — | US | claimed |
| US-11904020-B2 | Bicyclic peptide ligands specific for TREM2 | BICYCLETX LIMITED (GB) | 2024-02-20 | — | — | US | claimed |
| EP-4308586-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | BicycleTX Limited (GB) | 2024-01-24 | — | — | EP | claimed |
| CN-117337295-A | Bicyclic peptide ligands specific for TREM2 | 拜斯科技术开发有限公司 | 2024-01-02 | — | — | CN | claimed |
| EP-4274841-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| EP-4274839-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| CN-117062826-A | Antiinfective bicyclic peptide ligands | 拜斯科技术开发有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-117043176-A | Antiinfective bicyclic peptide ligands | 拜斯科技术开发有限公司 | 2023-11-10 | — | — | CN | claimed |
| WO-2023056388-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-04-06 | — | — | WO | claimed |
| WO-2023042201-A1 | ANTIMICROBIAL PEPTIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-03-23 | — | — | WO | claimed |
| US-6323219-B1 | PRODRUGS AND PEPTIDES FOR ANTIINFLAMMATORY AGENTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-11-27 | — | — | US | claimed |
| WO-2001083554-A2 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2001-11-08 | — | — | WO | claimed |
| JP-2001502360-A | — | — | 2001-02-20 | — | — | JP | claimed |
| EP-0948308-A1 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1999004752-A9 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1999004752-A2 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| EP-0833839-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1996040741-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040748-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| US-5523308-A | SERINE PROTEASES INHIBITORS; ORAL ANTICOAGULANTS; CHEMICAL INTERMEDIATES; DIPEPTIDES | ORTHO PHARMACEUTICAL CORPORATION | 1996-06-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11904020-B2 | Bicyclic peptide ligands specific for TREM2 | APP, TIMCC, ADM2 | ADAMTS4 2442/4885TAAR1 1614/4885PTGS2 1435/4885 |
| US-20240083944-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | ACE2, SARS1, TMPRSS2 | ADAMTS4 1269/4885TAAR1 4558/4885PTGS2 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.